Show simple item record

dc.contributor.authorAdderley, Helen
dc.contributor.authorAckermann, Christoph J
dc.contributor.authorCalifano, Raffaele
dc.date.accessioned2020-02-27T16:55:28Z
dc.date.available2020-02-27T16:55:28Z
dc.date.issued2020en
dc.identifier.citationAdderley H, Ackermann CJ, Califano R. Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line? Ann Transl Med. 2019;7(Suppl 8):S346.en
dc.identifier.pmid32016064en
dc.identifier.doi10.21037/atm.2019.09.116en
dc.identifier.urihttp://hdl.handle.net/10541/622785
dc.description.abstractComment on Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. [Lancet Oncol. 2019]en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.21037/atm.2019.09.116en
dc.titleErlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalAnnals of Translational Medicineen
dc.description.noteen]
refterms.dateFOA2020-03-03T13:14:55Z


Files in this item

Thumbnail
Name:
32016064.pdf
Size:
161.8Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record